Drug-Repositioning Approaches Based on Database
座間味, 義人 Tokushima University|Okayama University KAKEN研究者をさがす
濱野, 裕章 Tokushima University KAKEN研究者をさがす
新村, 貴博 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
相澤, 風花 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
八木, 健太 Tokushima University 徳島大学 教育研究者総覧
合田, 光寛 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
(井澤)石澤, 有紀 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
石澤, 啓介 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
medical information database
life science databases
Drug repositioning is a drug discovery strategy in which an existing drug is utilized as a therapeutic agent for a different disease. As information regarding the safety, pharmacokinetics, and formulation of existing drugs is already available, the cost and time required for drug development is reduced. Conventional drug repositioning has been dominated by a method involving the search for candidate drugs that act on the target molecules of an organism in a diseased state through basic research. However, recently, information hosted on medical information and life science databases have been used in translational research to bridge the gap between basic research in drug repositioning and clinical application. Here, we review an example of drug repositioning wherein candidate drugs were found and their mechanisms of action against a novel therapeutic target were identified via a basic research method that combines the findings retrieved from various medical and life science databases.
Frontiers in Pharmacology
Frontiers Media S.A.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
fphar_12_752174.pdf 1.55 MB